Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

DARE to PLAY is a topical sildenafil cream enhancing female arousal, available in select states as a compounded product while awaiting FDA approval. Clinical trials showed improved arousal sensation ...

Nogapendekin alfa inbakicept combined with BCG shows promise for BCG-unresponsive NMIBC CIS, with a 71% complete response rate in a single-arm trial. The European Medicines Agency's conditional ...

The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...

IsoPSA test analyzes prostate cancer-specific structural variants of PSA protein to aid biopsy decisions in men over 50 with elevated PSA levels. The FDA approved IsoPSA based on a large-scale, ...

Ibrahim explains the unique challenges men face after spinal cord injury, including neurogenic erectile dysfunction, ejaculatory dysfunction, and particularly the distinctive sperm abnormalities seen ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

In this interview, Seth P. Lerner, MD, discusses current recommendations for managing patients during the BCG shortage, what the FDA is doing to resolve the problem, and a SWOG trial testing a new ...

The decline in total testosterone was observed even among men with normal body mass index. From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures. Uncomplicated urinary tract infection is one of the most common indications for antimicrobial exposure in otherwise ...